Displaying drugs 5276 - 5300 of 5985 in total
Pumosetrag
Pumosetrag has been used in trials studying Gastroesophageal Reflux Disease.
Investigational
Matched Iupac: … N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-oxo-4H,7H-thieno[3,2-b]pyridine-6-carboxamide …
LY-377604
Ly377604 has been used in trials studying the treatment of Obesity.
Investigational
Matched Iupac: … 6-[4-(2-{[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino}-2-methylpropyl)phenoxy]pyridine-3-carboxamide …
Mavatrep
Mavatrep has been used in trials studying the treatment of Osteoarthritis, Knee.
Investigational
Matched Iupac: … 2-(2-{2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1H-1,3-benzodiazol-6-yl}phenyl)propan-2-ol …
Clinafloxacin
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Iupac: … 7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
8-Chloroadenosine
8-Chloroadenosine is under investigation in clinical trial NCT02509546 (8-chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Iupac: … (2R,3R,4S,5R)-2-(6-amino-8-chloro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol …
Ceralifimod
Ceralifimod is under investigation in clinical trial NCT01226745 (Phase 2 Extension Trial in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)).
Investigational
Matched Iupac: … 1-({6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic …
Olacaftor
Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).
Investigational
Matched Iupac: … N-(benzenesulfonyl)-6-[3-fluoro-5-(2-methylpropoxy)phenyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine …
Osoresnontrine
Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.).
Investigational
Matched Iupac: … 1-(oxan-4-yl)-6-[(pyridin-2-yl)methyl]-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one …
Zanzalintinib
Investigational
Matched Iupac: … N1-(4-fluorophenyl)-N'1-(4-{[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide …
25-Hydroxycholesterol
Experimental
Matched Iupac: … (1R,3aS,3bS,7S,9aR,9bS,11aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1H,2H,3H,3aH,3bH, …
APG-1387
APG-1387 is under investigation in clinical trial NCT04568265 (A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B).
Investigational
Matched Iupac: … (5S,8S,10aR)-3-(3-{[(5S,8S,10aR)-8-[(diphenylmethyl)carbamoyl]-5-[(2S)-2-(methylamino)propanamido]-6- ... [1,5]diazocin-3-yl]sulfonyl}benzenesulfonyl)-N-(diphenylmethyl)-5-[(2S)-2-(methylamino)propanamido]-6- …
Buprenorphine hemiadipate
Buprenorphine hemiadipate is under investigation in clinical trial NCT01582347 (Transfer of Subjects From Subutex/suboxone to RBP-6300).
Investigational
Matched Iupac: … 6-{[(1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy ... -13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7(12),8,10-trien-11-yl]oxy}-6-oxohexanoic …
VB-309
Investigational
Matched Iupac: … (2S,3R,4S,5S,6R)-2-{[(2R,3S,4R,5R,6S)-6-{[(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6H,6aH,7H,8H,10aH-benzo ... [c]isochromen-1-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol …
Bambermycins
Bambermycins are antibiotic complexes which are retrieved from the organism, Streptomyces bambergiensis. They are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.
Vet approved
Matched Iupac: … yl]oxy}oxan-2-yl]oxy}-4-hydroxy-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy ... 5R,6R)-4-(carbamoyloxy)-5-{[(2S,3R,4R,5S,6R)-3-acetamido-5-{[(2S,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6- ... methyl-5-{[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)carbamoyl]oxan-2- ... }methyl)oxan-2-yl]oxy}-3-hydroxy-6-({hydroxy[(2R)-2-hydroxy-3-oxo-3-{[(3E,7E,14E)-4,9,9,15,19-pentamethyl …
Narsoplimab
Thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, are associated with injury and dysregulation of microvascular endothelium and platelets. Evidence increasingly points to a role for the complement system in TMA.[A241030, A241040] Mannan-associated lectin-binding serine protease-2 (MASP-2) is a major effector in the complement lectin pathway.[A241030,...
Investigational
Nemvaleukin alfa
Investigational
Amphomycin
Vet approved
Matched Iupac: … carbamoyl]-2-carboxyethyl]carbamoyl}methyl)carbamoyl]-2-carboxyethyl]carbamoyl}-3-[(2S)-3-carboxy-2-[(3E)-10 …
Satoreotide tetraxetan
Investigational
Matched Iupac: … 2-[4-({[(1S)-1-{[(4R,7S,10S,13R,16S,19S)-10-(4-aminobutyl)-4-{[(1R)-1-carbamoyl-2-(4-hydroxyphenyl)ethyl …
Satoreotide trizoxetan
Investigational
Matched Iupac: … 4-{[(1S)-1-{[(4R,7S,10S,13R,16S,19S)-10-(4-aminobutyl)-4-{[(1R)-1-carbamoyl-2-(4-hydroxyphenyl)ethyl] …
Dotamtate Pb-212
Investigational
Matched Iupac: … lambda2-(212Pb)lead(2+) 2-[7-({[(1R)-1-{[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-{[(1S,2R)-1-carboxy …
AUROVERTIN B
Experimental
Matched Iupac: … (1S,3S,4S,5S,7R,8S)-7-ethyl-4-hydroxy-3-[(1E,3E,5E)-6-(4-methoxy-5-methyl-2-oxo-2H-pyran-6-yl)hexa-1,3,5 …
Crovalimab
Crovalimab is under investigation in clinical trial NCT03157635 (Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria).
Investigational
Temafloxacin
Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.
Withdrawn
Matched Iupac: … 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
Displaying drugs 5276 - 5300 of 5985 in total